Monoclonal antibody therapies, such as trastuzumab and pertuzumab, and receptor tyrosine kinase inhibitors, such as Lapatinib, directed against the Human Epidermal Receptors (HER) have vastly improved HER2+ breast cancer patient outcomes2,3. Here, ERBB2 is linked to breast carcinoma.